In a large and open prospective multicenter trial of 12,250 cycles from 2,378 women,
contraceptive efficacy, clinical tolerance and acceptability of a new monophasic …

The contraceptive efficacy, tolerance, and safety of a new monophasic oral contraceptive
that combines 75 mcg gestodene (delta-15-levonorgestrel) and 30 mcg ethinyl estradiol …

The monophasic combination preparation containing 30 micrograms ethinyl estradiol and
75 micrograms gestodene was tested for contraceptive reliability, cycle control and …

The contraceptive efficacy, cycle control, safety, and subject acceptance of the new
contraceptive (OC) preparations containing gestodene (GTD) plus ethinyl estradiol (EE) are …

An open prospective clinical trial designed to evaluate the efficacy and safety of the
combined hormonal oral contraceptive (OC) containing 75 μg gestodene plus 30 μg ethinyl …

The aim of this study was to compare contraceptive reliability, cycle control, and tolerance of
an oral contraceptive containing 20 μg ethinylestradiol (EE2) and 75 μg gestodene (GSD) …

An open label, non-comparative study was carried out in 22 women over a total of five
cycles. After an untreated cycle, oral administration of 20 μg ethinyl estradiol (EE) with 50 μg …

The efficacy, cycle control, subjective complaints, and safety of monophasic preparations of
the oral contraceptives containing gestodene 75 mcg plus ethinyl estradiol 30 mcg versus …

This long-term, open-label, multicenter study investigated the clinical efficacy and tolerability
of a monophasic oral contraceptive containing 20 μg ethinylestradiol and 75 μ ggestodene …

The aim of this study was to compare contraceptive reliability, cycle control and tolerance of
an oral contraceptive containing 20 μg ethinylestradiol and 75 μg gestodene, with a …